Related Experiment Video
Updated: May 24, 2026

Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus
Published on: January 28, 2019
Effect of rotavirus vaccine on reducing acute gastroenteritis in a large outpatient pediatric network
Sheila M Nolan1, Priya Prasad, Alexander G Fiks
1Division of Infectious Diseases, The Children's Hospital of Philadelphia, 34th St and Civic Center Blvd, Philadelphia, PA 19104, USA. sheilanolan@hotmail.com
Insights
The rotavirus vaccine (RVV) significantly reduced acute gastroenteritis (AGE) in children in 2007. However, no difference was observed between vaccinated and unvaccinated children in 2008, warranting further investigation.
Area of Science:
- Pediatric infectious diseases
- Vaccinology
- Public health
Background:
- Rotavirus is a leading cause of severe acute gastroenteritis (AGE) in infants and young children globally.
- The introduction of rotavirus vaccine (RVV) aimed to reduce the burden of rotavirus disease.
- Understanding vaccine effectiveness in real-world primary care settings is crucial.
Purpose of the Study:
- To evaluate the impact of RVV on AGE management in primary care.
- To assess RVV effectiveness during the initial rotavirus seasons post-introduction.
- To analyze AGE-related visits, calls, and episodes in relation to RVV uptake.
Main Methods:
- A retrospective cohort study was conducted in 33 pediatric practices in Philadelphia.
- Participants included children born between February 2006 and February 2008.
- Data on RVV receipt and AGE outcomes were collected.
Main Results:
- AGE visits decreased from 3.0 to 1.8 per 100 visits between 2005 and 2008.
- In 2007, RVV showed 53% effectiveness against AGE calls and 46% against AGE episodes.
- No significant difference in outcomes was observed between vaccinated and unvaccinated children in 2008.
Conclusions:
- RVV was associated with a significant reduction in outpatient AGE in 2007.
- The lack of a detected difference in 2008 suggests a need for further research.
- Continued monitoring is essential to understand long-term RVV impact and potential confounding factors.
Objectives:
To measure the effect of rotavirus vaccine (RVV) on acute gastroenteritis (AGE) managed by primary care physicians in the first 2 rotatvirus seasons following the introduction of RVV.
Design:
Retrospective cohort study.
Setting:
Practice-based network composed of 33 ambulatory pediatric practices in Philadelphia, Pennsylvania.
Participants:
All children born from February 22, 2006 (date of RVV licensure), through February 29, 2008, and who received care at any network site.
Main Exposure:
Receipt of RVV.
Outcome Measures:
The primary outcomes were AGE-related office visits, telephone calls, and episodes (composite outcome consisting of all visits and calls within a 10-day period).
Results:
Rates of AGE visits in the 2 rotavirus seasons following the introduction of RVV steadily decreased from 3.0 AGE visits per 100 total office visits in the 2005 season to 1.8 in the 2008 season. In 2007, vaccinations were administered to 9351 of 13 951 vaccine-eligible children (67.0%), and in 2008, they were administered to 9958 of 10 728 (92.8%). Among RVV-immunized children in 2007, AGE calls and episodes were significantly reduced with vaccine effectiveness of 53% and 46%, respectively. No significant difference was seen between RVV-immunized and RVV-nonimmunized children for any outcome in 2008.
Conclusions:
Rotavirus vaccine was associated with a significant reduction in outpatient AGE calls and episodes among immunized children in our network in 2007. Despite a reduction in winter AGE rates in the network, no difference was detected between RVV-immunized and RVV-nonimmunized children for any outcome in 2008. Further study is needed to understand the lack of vaccine effect in 2008.
Related Concept Videos
Bacterial Gastroenteritis
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Vaccinations

